High‐dose versus standard‐dose radiation therapy for cervical esophageal cancer: Retrospective single‐institution study. Issue 1 (12th December 2018)

• Record Type: Journal Article
• Authors: Kim, Tae Hyung; Lee, Ik Jae; Kim, Ji‐Hyun; Lee, Chang Geol; Lee, Yong Chan; Kim, Jun Won
• Is Part Of: Head & neck. Volume 41:Issue 1(2019)
• Page Start: 146
• Page End: 153
• Publication Date: 2018-12-12
• Subjects: cervical esophageal carcinoma -- chemoradiation -- dose escalation; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.25483
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: To evaluate the role of definitive radiotherapy using higher‐than‐standard‐dose radiation of 50 Gy for carcinoma of the cervical esophagus (CCE). Methods: We reviewed 79 patients with stage I‐III CCE, treated between 2000 and 2012. Patients received 5‐fluorouracil/cisplatin‐based chemotherapy concurrently and were divided into high‐dose (≥59.4 Gy, n = 44) and standard‐dose (<59.4 Gy, n = 35) groups. Results: The median follow‐up was 35 months for surviving patients. The high‐dose group had significantly better 3‐year local (90.0% vs 60.4%, P = .001) and locoregional (70.4% vs 45.3%, P = .04) control. Progression‐free (45.4% vs 37.5%, P = .32) and overall (58.4% vs 49.1%, P = .69) survival rates were not different. High‐dose radiation was an independent prognostic factor for locoregional control ( P = .04). No differences in late toxicities (esophageal stenosis or tracheoesophageal fistula) were observed. Conclusion: High‐dose radiation for CCE improves local and locoregional control, without increasing severe toxicities.